利妥昔单抗对于非霍奇金淋巴瘤的治疗及其药物经济学  

Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin's lymphoma

作　　者：石浩强[1] 沈阳[2] 叶莹琼[1] 张芬琴[2] 陶静[1] 蔡卫民[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院药剂科,上海200025 [2]上海交通大学医学院附属瑞金医院血液科,上海200025

出　　处：《药学服务与研究》2007年第5期332-334,共3页Pharmaceutical Care and Research

摘　　要：目的:阐述利妥昔单抗对于非霍奇金淋巴瘤的疗效和药物的不良反应,并尝试探讨其药物经济学。方法:借鉴国外的研究并结合本院血液科对于这方面的探索,采用非传统的药物经济学模式来评价利妥昔单抗的治疗方案。结果:从药物经济学的角度而言,利妥昔单抗联合环磷酰胺+多柔比星(阿霉素)+长春新碱+泼尼松(CHOP)方案治疗非霍奇金淋巴瘤较传统单用CHOP方案优势明显。结论:利妥昔单抗具有较好的疗效和安全性,也是治疗非霍奇金淋巴瘤较经济的方法。Objective：To elucidate the efficacy and adverse drug reaction of rituximab in treatment of non-Hodgkin＇s lymphoma.Methods：According to the oversea investigation and research carried out in the department of hematology in Ruijin Hospital,untraditional pharmacoeconomic method was used to evaluate the therapeutic protocol of rituximab.Results：Rituximab plus CHOP chemotherapy（cyclophosphamide,doxorubicin,vincristine and prednisone） had better therapeutic results in the treatment of non-Hodgkin＇s lymphoma than traditional CHOP chemotherapy alone in the aspect of pharmacoeconomics.Conclusion：Rituximab is a fine and phamacoeconomic choice for non-Hodgkin＇s lymphoma with satisfactory efficacy and safety.

关 键 词：利妥昔单抗 淋巴瘤 非霍奇金 经济学 药学 

分 类 号：R956[医药卫生—药学] R191.1